SERUM ADIPONECTIN – A POTENTIAL PROGNOSTIC BIOMARKER IN CHRONIC SYSTOLIC HEART FAILURE

You are here

Laboratorinė medicina. 2019,
t. 21,
Nr. 4,
p. 187 -
193

Summary

The cur rent con cept of chronic heart failure treats the condition as a complex process, a systemic disorder, which in volves im mune ac ti va tion, metabolic alterations and processes in skeletal muscle. Adipocyte- derived cytokines (adipokines) exert many biological activities, including an important regulatory role in myocardial function. One of such adipokines is adiponectin. Apart from being produced in adipose tissue it is also synthesized in cardiac muscle cells and cardiac connective tissue and seems to have a critical signaling function in the heart. Multiple experimental studies have high lighted the pleotropic beneficial effects of adiponectin. This adipokine was shown to be granted with insuline sensitizing, antiathero sclerotic, anti-inflammatory as well as cardioprotective effects. Nevertheless elevated adiponectin levels were repeatedly documented in patients with chronic systolic heart failure. More over they have been linked to increase risk of recurrent cardiovascular events and mortality. The causes of this counter - intuitive increase in serum adiponectin levels in chronic heart failure are still obscure. During 25 years of adiponectin research many complexities concerning its role in pathogenesis of heart failure as well as out come prediction were revealed. And it seems that over simplification in this case is not possible. Further studies are needed.

© 2024, Lithuanian Society of Laboratory Medicine
randomness